Research Grant
[Cite as https://purl.org/au-research/grants/nhmrc/1048312]Researchers: A/Pr Andrew Wei (Principal investigator) , A/Pr Mark Levis , Prof Andrew Roberts , Prof Kenneth Bradstock , Prof Michael Murray
Brief description Acute myeloid leukaemia is a devastating blood cancer which affects almost 1000 Australians annually. One quarter have a mutation affecting a gene called FLT3, which results in aggressive leukaemia rarely cured by chemotherapy alone. Dr Andrew Wei from the Alfred Hospital will lead a nationwide randomised clinical trial through the Australasian Leukaemia and Lymphoma Group network to investigate whether a targeted FLT3 inhibitor small molecule called Sorafenib will improve outcomes for patients with this poor risk blood cancer.
Funding Amount $AUD 1,169,549.62
Funding Scheme Project Grants
Notes Standard Project Grant
- nhmrc : 1048312
- PURL : https://purl.org/au-research/grants/nhmrc/1048312